NZ548367A - Non-nucleoside reverse transcriptase inhibitors - Google Patents

Non-nucleoside reverse transcriptase inhibitors

Info

Publication number
NZ548367A
NZ548367A NZ548367A NZ54836704A NZ548367A NZ 548367 A NZ548367 A NZ 548367A NZ 548367 A NZ548367 A NZ 548367A NZ 54836704 A NZ54836704 A NZ 54836704A NZ 548367 A NZ548367 A NZ 548367A
Authority
NZ
New Zealand
Prior art keywords
mmol
difluoro
tetrahydro
cyclopropa
fluoro
Prior art date
Application number
NZ548367A
Other languages
English (en)
Inventor
Christian Sund
Nathalie Roue
Stefan Lindstrom
Dmitry Antonov
Christer Sahlberg
Katarina Jansson
Original Assignee
Medivir Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0400021A external-priority patent/SE0400021D0/xx
Priority claimed from SE0400585A external-priority patent/SE0400585D0/xx
Application filed by Medivir Ab filed Critical Medivir Ab
Publication of NZ548367A publication Critical patent/NZ548367A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NZ548367A 2004-01-08 2004-12-30 Non-nucleoside reverse transcriptase inhibitors NZ548367A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0400021A SE0400021D0 (sv) 2004-01-08 2004-01-08 Non-nucleoside reverse transcriptase inhibitors
SE0400585A SE0400585D0 (sv) 2004-03-09 2004-03-09 NNRTI Antivirals
PCT/SE2004/002034 WO2005066131A1 (en) 2004-01-08 2004-12-30 Non-nucleotide reverse transcriptase inhibitors

Publications (1)

Publication Number Publication Date
NZ548367A true NZ548367A (en) 2010-06-25

Family

ID=34752289

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ548367A NZ548367A (en) 2004-01-08 2004-12-30 Non-nucleoside reverse transcriptase inhibitors

Country Status (15)

Country Link
US (1) US7915295B2 (enExample)
EP (1) EP1701942B1 (enExample)
JP (1) JP4762917B2 (enExample)
AT (1) ATE451357T1 (enExample)
AU (1) AU2004312284B2 (enExample)
BR (1) BRPI0418306B8 (enExample)
CA (1) CA2550187C (enExample)
DE (1) DE602004024584D1 (enExample)
DK (1) DK1701942T3 (enExample)
EA (1) EA009700B1 (enExample)
ES (1) ES2337794T3 (enExample)
IL (1) IL176740A (enExample)
NZ (1) NZ548367A (enExample)
SG (1) SG149070A1 (enExample)
WO (1) WO2005066131A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050033663A (ko) * 2002-09-05 2005-04-12 메디비르 아베 비-뉴클레오시드 역전사효소 억제제
US7388008B2 (en) 2004-08-02 2008-06-17 Ambrilia Biopharma Inc. Lysine based compounds
US20060287316A1 (en) * 2005-04-27 2006-12-21 Ambrilia Biopharma Inc. Method for improving pharmacokinetics of protease inhibitors and protease inhibitor precursors
WO2007062526A1 (en) 2005-11-30 2007-06-07 Ambrilia Biopharma Inc. Lysine-based prodrugs of aspartyl protease inhibitors and processes for their preparation
GB0608876D0 (en) * 2006-05-05 2006-06-14 Medivir Ab Combination therapy
AU2007254325B2 (en) * 2006-05-15 2012-05-10 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
ES2628730T3 (es) 2006-09-21 2017-08-03 Taimed Biologics, Inc. Inhibidores de proteasa
EP3250552B1 (en) * 2015-01-30 2019-03-27 Genentech, Inc. Therapeutic compounds and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9906933A (pt) * 1998-01-16 2001-11-27 Medivir Ab Antiviróticos
WO1999051613A1 (en) * 1998-04-03 1999-10-14 Medivir Ab Prodrugs of phosphorous-containing pharmaceuticals
SE0100733D0 (sv) 2001-03-05 2001-03-05 Medivir Ab Non-nucleoside reverse transcriptase inhibitors
SE0102867D0 (sv) * 2001-08-28 2001-08-28 Medivir Ab Non-nucleoside reverse transcriptase inhibitors
KR20050033663A (ko) * 2002-09-05 2005-04-12 메디비르 아베 비-뉴클레오시드 역전사효소 억제제

Also Published As

Publication number Publication date
AU2004312284A1 (en) 2005-07-21
US7915295B2 (en) 2011-03-29
BRPI0418306B1 (pt) 2018-09-18
JP2007519640A (ja) 2007-07-19
SG149070A1 (en) 2009-01-29
DK1701942T3 (da) 2010-04-06
BRPI0418306A (pt) 2007-05-02
IL176740A0 (en) 2006-10-31
CA2550187A1 (en) 2005-07-21
CA2550187C (en) 2012-08-07
WO2005066131A1 (en) 2005-07-21
EA200601289A1 (ru) 2006-12-29
IL176740A (en) 2011-09-27
EP1701942A1 (en) 2006-09-20
ATE451357T1 (de) 2009-12-15
US20080070951A1 (en) 2008-03-20
ES2337794T3 (es) 2010-04-29
AU2004312284B2 (en) 2010-08-05
BRPI0418306B8 (pt) 2021-05-25
AU2004312284A2 (en) 2005-07-21
HK1101400A1 (en) 2007-10-18
EP1701942B1 (en) 2009-12-09
DE602004024584D1 (de) 2010-01-21
EA009700B1 (ru) 2008-02-28
JP4762917B2 (ja) 2011-08-31

Similar Documents

Publication Publication Date Title
CA2550187C (en) Non-nucleoside reverse transcriptase inhibitors
AU2004249372B2 (en) Indole derivatives as serotonin reuptake inhibitors
AU2003260492B2 (en) Non-nucleoside reverse transcriptase inhibitors
CA2438524C (en) Cyclopropaheterocycles as non-nucleoside reverse transcriptase inhibitors
AU2002308231A1 (en) Cyclopropaheterocycles as non-nucleoside reverse transcriptase inhibitors
US6610714B2 (en) Non-nucleoside reverse transcriptase inhibitors
CN1926108B (zh) 非核苷酸逆转录酶抑制剂
MXPA06007726A (en) Non-nucleotide reverse transcriptase inhibitors
HK1101400B (en) Non-nucleotide reverse transcriptase inhibitors
AU2002311031A1 (en) Urea and thiourea derivatives as non-nucleoside reverse transcriptase inhibitors

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 DEC 2015 BY LEA

Effective date: 20141211

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 DEC 2016 BY LEA SKYLLERSTEDT

Effective date: 20151210

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 DEC 2017 BY CPA GLOBAL (PATRAFEE)

Effective date: 20161208

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 DEC 2018 BY CPA GLOBAL(PATRAFEE) AB

Effective date: 20171130

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 DEC 2019 BY CPA GLOBAL(PATRAFEE) AB

Effective date: 20181217

LAPS Patent lapsed